Open AccessUrsodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
Author(s) -
M. Yu. Nadinskaia,
M. V. Maevskaya,
В. Т. Ивашкин,
Х. Б. Кодзоева,
И. Ю. Пирогова,
Е. В. Чесноков,
Alexander Nersesov,
Jamilya Kaibullayeva,
Akzhan Konysbekova,
Aigul Raissova,
Ф. И. Хамрабаева,
Е. Б. Зуева
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i10.959
Subject(s) - nonalcoholic fatty liver disease , medicine , ursodeoxycholic acid , gastroenterology , steatosis , dyslipidemia , fatty liver , fibrosis , liver function tests , alanine transaminase , disease
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Weight loss is a key factor for successful NAFLD and CVD therapy. Ursodeoxycholic acid (UDCA), which is one of the first-line therapeutic agents for treatment of NAFLD, is reported to have a beneficial effect on dyslipidemia and ASCVD risk because of antioxidant properties.